Evidence map›Paper›PMID 29468060›Full record

ArticleMolecular and clinical oncology2018

Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia.

Carmelo Gurnari, Paola Panetta, Emiliano Fabiani, Anna Maria Nardone, Diana Postorivo, Giulia Falconi, Luca Franceschini, Manuela Rizzo, Vito Mario Rapisarda, Eleonora De Bellis and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Carmelo GurnariDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Paola PanettaHematology Department, Tor Vergata University Hospital, Rome, Italy.
Emiliano FabianiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Anna Maria NardoneLaboratory of Medical Genetics, Tor Vergata Clinic, Rome, Italy.
Diana PostorivoLaboratory of Medical Genetics, Tor Vergata Clinic, Rome, Italy.
Giulia FalconiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Luca FranceschiniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Manuela RizzoHematology Department, Tor Vergata University Hospital, Rome, Italy.
Vito Mario RapisardaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Eleonora De BellisDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Francesco Lo-CocoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization classifies atypical chronic myeloid leukemia (aCML) as a myeloproliferative/myelodisplastic hematological disorder. The primary manifestations are leukocytosis with disgranulopoiesis, absence of basophilia and/or monocytosis, splenomegaly and absence of Philadelphia chromosome or BCR/ABL fusion. Overall 50-65% of patients demonstrate karyotypic abnormalities, although no specific cytogenetic alterations have been associated with this disease. X chromosome alterations have been rarely reported in myeloid malignancies. Although Isodicentric X, idic(X)(q13) is well known in females with myelodysplastic syndromes (MDS), little data are available on X isochromosome and its pathogenetic potential in these disorders. i(X)(p10) is observed in a variety of hematologic malignancies, both myeloid and lymphoid, as a unique abnormality, as well as part of a more complex karyotype, in females and less frequently in male patients. The present report describes the first patient with aCML, with documented isolated i(X)(p10), who developed a secondary acute myeloid leukemia (sAML).

Indexed as

atypical chronic myeloid leukemiaisochromosome(X)(p10)secondary acute myeloid leukemia

Identifiers

PMID29468060
PMCPMC5791424
OpenAlexW2777733838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.